Tardive Dyskinesia: Risk Factors

Risk of tardive dyskinesia is influenced by treatment exposure and individual factors. Longer cumulative exposure to dopamine receptor-blocking medicines is relevant, but the condition does not occur in everyone. Age, previous movement effects and other clinical features may also affect risk. Second-generation drugs do not eliminate the possibility.

Tardive dyskinesia is a movement disorder associated with exposure to dopamine receptor-blocking medicines. It often develops after ongoing treatment, although patterns vary. Movements can persist and may affect function or wellbeing. It differs from acute dystonia, akathisia and drug-induced parkinsonism, making accurate assessment important rather than treating all movement changes as one problem.

Risk factors describe probabilities rather than a precise forecast. They cannot identify exactly who will develop symptoms or justify ignoring a new movement in someone considered low risk. Assessment also considers other medicines that block dopamine, including some used outside psychiatry. A history of exposure remains important even if the current prescription has changed. Prevention involves thoughtful prescribing, review and monitoring rather than promising a risk-free drug. The person’s need for symptom control must be balanced with awareness of long-term effects through shared clinical decisions.

Cumulative exposure includes relevant medicines from earlier treatment, not only the current prescription. Some dopamine-blocking agents are used for nausea or other non-psychiatric indications. A complete history can therefore reveal exposure that a psychiatric medication list misses. Risk review should remain individual and avoid suggesting that a low current dose or a newer agent makes screening unnecessary.

Further reading: National Institute of Mental Health; DailyMed prescribing information; US FDA medicine information.